Company news

Shionogi & Co., Ltd. news in 2025

Shionogi & Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Shionogi - Announcement of the Conclusion of a Joint Research and Development Agreement and Investment Agreement with Salubritas Therapeutics Aimed at Demonstrating the Improvements of Hearing Function

December 24, 2025

Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA

December 22, 2025

BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update

December 11, 2025

ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain

October 17, 2025

Gareth Morgan Named President of Qpex Biopharma, Inc.

October 15, 2025

ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir

October 15, 2025

ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025

October 9, 2025

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek

September 3, 2025

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure

September 2, 2025

ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment

July 14, 2025

Shionogi Implements Stibo Systems MDM Solution

July 10, 2025

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan

July 3, 2025

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate

July 2, 2025

Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Treatment of COVID-19 in Pediatric Patients Aged 6 Years and Older

June 30, 2025

FY2024 Supplement

May 12, 2025

FY2024 Financial Results

May 12, 2025

Agreement on the Absorption-Type Split of JT Pharmaceutical Division and Acquisition of Shares of Akros, and Commencement of Tender Offer for TORII

May 7, 2025

Shionogi & Co., Ltd. - Exclusive Licensing Agreement with Link Healthcare, a Clinigen Company for Cefiderocol in Australia and New Zealand

April 3, 2025

Shionogi & Co., Ltd. - Approval for Fetroja in South Korea

February 24, 2025

Shionogi Obtains Domestic Manufacturing and Marketing Approval for the Digital Therapeutic App ENDEAVORRIDE for Pediatric Attention-Deficit, Hyperactivity Disorder

February 19, 2025

Calls in 2025

Decks in 2025